REGN.NASDAQRegeneron Pharmaceuticals, INC
Form 4: Regeneron Pharmaceuticals Executive Sells Shares
Sentiment:
Insider Transaction (Form 4)
Andrew J Murphy, Co-Chief Scientific Officer of Regeneron Pharmaceuticals, Inc., sold 4,147 shares of common stock on October 13, 2026.
Summary
- Option exercise/conversion: acquired 17,000 Common Stock at $381.92 ($6,492,640) on October 13, 2026; holds 64,833 after (Direct).
- Tax/exercise-price withholding: disposed of 12,853 Common Stock at $754.58 ($9,698,617) on October 13, 2026; holds 51,980 after (Direct).
- Open-market sale: disposed of 6 Common Stock at $753.76 ($4,523) on October 14, 2026; holds 51,974 after (Direct).
- Open-market sale: disposed of 35 Common Stock at $755.91 ($26,457) on October 14, 2026; holds 51,939 after (Direct).
- Open-market sale: disposed of 16 Common Stock at $757.68 ($12,123) on October 14, 2026; holds 51,923 after (Direct).
- Open-market sale: disposed of 24 Common Stock at $758.16 ($18,196) on October 14, 2026; holds 51,899 after (Direct).
- Open-market sale: disposed of 14 Common Stock at $759.96 ($10,639) on October 14, 2026; holds 51,885 after (Direct).
- Open-market sale: disposed of 74 Common Stock at $760.65 ($56,288) on October 14, 2026; holds 51,811 after (Direct).
- Open-market sale: disposed of 27 Common Stock at $761.36 ($20,557) on October 14, 2026; holds 51,784 after (Direct).
- Open-market sale: disposed of 55 Common Stock at $762.57 ($41,941) on October 14, 2026; holds 51,729 after (Direct).
- Open-market sale: disposed of 25 Common Stock at $763.76 ($19,094) on October 14, 2026; holds 51,704 after (Direct).
- Open-market sale: disposed of 219 Common Stock at $764.40 ($167,404) on October 14, 2026; holds 51,485 after (Direct).
- Open-market sale: disposed of 271 Common Stock at $765.39 ($207,421) on October 14, 2026; holds 51,214 after (Direct).
- Open-market sale: disposed of 279 Common Stock at $766.47 ($213,845) on October 14, 2026; holds 50,935 after (Direct).
- Open-market sale: disposed of 192 Common Stock at $767.39 ($147,339) on October 14, 2026; holds 50,743 after (Direct).
- Open-market sale: disposed of 105 Common Stock at $768.33 ($80,675) on October 14, 2026; holds 50,638 after (Direct).
- Open-market sale: disposed of 127 Common Stock at $769.30 ($97,701) on October 14, 2026; holds 50,511 after (Direct).
- Open-market sale: disposed of 12 Common Stock at $770.20 ($9,242) on October 14, 2026; holds 50,499 after (Direct).
- Open-market sale: disposed of 283 Common Stock at $771.56 ($218,351) on October 14, 2026; holds 50,216 after (Direct).
- Open-market sale: disposed of 211 Common Stock at $772.56 ($163,010) on October 14, 2026; holds 50,005 after (Direct).
- Open-market sale: disposed of 224 Common Stock at $773.40 ($173,242) on October 14, 2026; holds 49,781 after (Direct).
- Open-market sale: disposed of 121 Common Stock at $774.48 ($93,712) on October 14, 2026; holds 49,660 after (Direct).
- Open-market sale: disposed of 376 Common Stock at $775.46 ($291,573) on October 14, 2026; holds 49,284 after (Direct).
- Open-market sale: disposed of 66 Common Stock at $776.31 ($51,236) on October 14, 2026; holds 49,218 after (Direct).
- Open-market sale: disposed of 38 Common Stock at $777.76 ($29,555) on October 14, 2026; holds 49,180 after (Direct).
- Open-market sale: disposed of 454 Common Stock at $778.64 ($353,503) on October 14, 2026; holds 48,726 after (Direct).
- Open-market sale: disposed of 380 Common Stock at $779.59 ($296,244) on October 14, 2026; holds 48,346 after (Direct).
- Open-market sale: disposed of 463 Common Stock at $780.63 ($361,432) on October 14, 2026; holds 47,883 after (Direct).
- Open-market sale: disposed of 50 Common Stock at $781.47 ($39,074) on October 14, 2026; holds 47,833 after (Direct).
- Option exercise/conversion: disposed of 17,000 Non-Qualified Stock Option (right to buy) on October 13, 2026; holds 17,000 after (Direct).
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a mildly negative but low-conviction signal: an insider sold $3,204,376 of stock under a pre-arranged Rule 10b5-1 plan, which is typically routine.
Insider Transactions
Andrew J Murphy — Officer (Co-Chief Scientific Officer)
Transaction made under a Rule 10b5-1 trading plan.
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-10-13 | Option exercise/conversion | Common Stock | 17,000 | $382 | $6.5M | 64,833 |
| 2026-10-13 | Tax/exercise-price withholding | Common Stock | 12,853 | $755 | $9.7M | 51,980 |
| 2026-10-14 | Open-market sale | Common Stock | 6 | $754 | $4.5K | 51,974 |
| 2026-10-14 | Open-market sale | Common Stock | 35 | $756 | $26.5K | 51,939 |
| 2026-10-14 | Open-market sale | Common Stock | 16 | $758 | $12.1K | 51,923 |
| 2026-10-14 | Open-market sale | Common Stock | 24 | $758 | $18.2K | 51,899 |
| 2026-10-14 | Open-market sale | Common Stock | 14 | $760 | $10.6K | 51,885 |
| 2026-10-14 | Open-market sale | Common Stock | 74 | $761 | $56.3K | 51,811 |
| 2026-10-14 | Open-market sale | Common Stock | 27 | $761 | $20.6K | 51,784 |
| 2026-10-14 | Open-market sale | Common Stock | 55 | $763 | $41.9K | 51,729 |
| 2026-10-14 | Open-market sale | Common Stock | 25 | $764 | $19.1K | 51,704 |
| 2026-10-14 | Open-market sale | Common Stock | 219 | $764 | $167.4K | 51,485 |
| 2026-10-14 | Open-market sale | Common Stock | 271 | $765 | $207.4K | 51,214 |
| 2026-10-14 | Open-market sale | Common Stock | 279 | $766 | $213.8K | 50,935 |
| 2026-10-14 | Open-market sale | Common Stock | 192 | $767 | $147.3K | 50,743 |
| 2026-10-14 | Open-market sale | Common Stock | 105 | $768 | $80.7K | 50,638 |
| 2026-10-14 | Open-market sale | Common Stock | 127 | $769 | $97.7K | 50,511 |
| 2026-10-14 | Open-market sale | Common Stock | 12 | $770 | $9.2K | 50,499 |
| 2026-10-14 | Open-market sale | Common Stock | 283 | $772 | $218.4K | 50,216 |
| 2026-10-14 | Open-market sale | Common Stock | 211 | $773 | $163.0K | 50,005 |
| 2026-10-14 | Open-market sale | Common Stock | 224 | $773 | $173.2K | 49,781 |
| 2026-10-14 | Open-market sale | Common Stock | 121 | $774 | $93.7K | 49,660 |
| 2026-10-14 | Open-market sale | Common Stock | 376 | $775 | $291.6K | 49,284 |
| 2026-10-14 | Open-market sale | Common Stock | 66 | $776 | $51.2K | 49,218 |
| 2026-10-14 | Open-market sale | Common Stock | 38 | $778 | $29.6K | 49,180 |
| 2026-10-14 | Open-market sale | Common Stock | 454 | $779 | $353.5K | 48,726 |
| 2026-10-14 | Open-market sale | Common Stock | 380 | $780 | $296.2K | 48,346 |
| 2026-10-14 | Open-market sale | Common Stock | 463 | $781 | $361.4K | 47,883 |
| 2026-10-14 | Open-market sale | Common Stock | 50 | $781 | $39.1K | 47,833 |
| 2026-10-13 | Option exercise/conversion | Non-Qualified Stock Option (right to buy) | 17,000 | — | — | 17,000 |
Key Dates
| Date | Description |
|---|---|
| 2026-10-13 | Option exercise/conversion (17,000 shares) |
| 2026-10-13 | Tax/exercise-price withholding (12,853 shares) |
| 2026-10-14 | Open-market sale (6 shares) |
| 2026-10-14 | Open-market sale (35 shares) |
| 2026-10-14 | Open-market sale (16 shares) |
| 2026-10-14 | Open-market sale (24 shares) |
| 2026-10-14 | Open-market sale (14 shares) |
| 2026-10-14 | Open-market sale (74 shares) |
| 2026-10-14 | Open-market sale (27 shares) |
| 2026-10-14 | Open-market sale (55 shares) |
| 2026-10-14 | Open-market sale (25 shares) |
| 2026-10-14 | Open-market sale (219 shares) |
| 2026-10-14 | Open-market sale (271 shares) |
| 2026-10-14 | Open-market sale (279 shares) |
| 2026-10-14 | Open-market sale (192 shares) |
| 2026-10-14 | Open-market sale (105 shares) |
| 2026-10-14 | Open-market sale (127 shares) |
| 2026-10-14 | Open-market sale (12 shares) |
| 2026-10-14 | Open-market sale (283 shares) |
| 2026-10-14 | Open-market sale (211 shares) |
| 2026-10-14 | Open-market sale (224 shares) |
| 2026-10-14 | Open-market sale (121 shares) |
| 2026-10-14 | Open-market sale (376 shares) |
| 2026-10-14 | Open-market sale (66 shares) |
| 2026-10-14 | Open-market sale (38 shares) |
| 2026-10-14 | Open-market sale (454 shares) |
| 2026-10-14 | Open-market sale (380 shares) |
| 2026-10-14 | Open-market sale (463 shares) |
| 2026-10-14 | Open-market sale (50 shares) |
| 2026-10-13 | Option exercise/conversion (17,000 shares) |
Keywords
insider transaction, Form 4, REGN, REGENERON PHARMACEUTICALS, INC., bearish, Andrew J Murphy
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.